In line with the above result that STING knockdown attenuated the tumor growth inhibition effect of bicalutamide/docetaxel/anti-PD1 blockade on the xenograft mouse model, the percentage of CD3+ and CD8+ T cells was decreased in RM1 STING shRNA-bearing tumor samples after combined treatment, compared with control shRNA, although the percentage of T cells showed no difference in treatment-naive tumors between STING shRNA and control shRNA (Figure S8B-C). This evidence concerns the gene STING1 and neoplasm.